Kailera Therapeutics, Inc. (KLRA) Completes Enrollment in Three Phase 3 Obesity Trials

Kailera completed enrollment in all three KaiNETIC global Phase 3 trials of ribupatide injection for obesity/overweight. Topline data from KaiNETIC-1, -2, and -3 are expected in mid-2028.Material DetailsContext by AI AnalystThis is a mid-to-late development milestone confirming program execution to…